
|Videos|April 6, 2016
How Renal Function and Comorbidities Affect Dosing for NOACs
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses how a patient's renal function and comorbidities affect dosing regimens for novel oral anticoagulants.
Advertisement
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses how a patient’s renal function and comorbidities affect dosing regimens for novel oral anticoagulants.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Removes Black Boxed Warning From Hormone Therapies for Menopause
2
Major Review Finds No Link Between Maternal Tylenol and Autism Spectrum Disorder, ADHD
3
Inclisiran Plus Usual Care Enhances LDL-C Control Post-Acute Coronary Syndrome
4
Advanced Wearable Accelerometer Shows Promise in Detecting Functional Capacity and Outcomes in Heart Failure Patients
5
















































































































































































































